Pharmaceuticals

Artelo Biosciences

Artelo Biosciences released FY2025 9 Months Earnings on November 12 (EST), with actual revenue of USD 0 and actual EPS of USD -13.9136

Artelo Biosciences released FY2025 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -3.97 (forecast USD -0.82)

Nasdaq-listed Artelo Biosciences Completes $3 Million Rights Offering

Artelo Biosciences released FY2025 Semi-Annual Earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -9.795

Artelo Biosciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -5.6114 (forecast USD -4.19)

Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12

D. Boral Capital Upgrades Artelo to Buy

Artelo Biosciences Announces Positive Preclinical Results for Antidepressant ART12.11

Artelo Biosciences reports positive results for first-in-human study of ART26.12

Artelo Biosciences, Inc. Completes $1.425 Million Private Placement Financing

D. Boral Capital downgrades Artelo Biosciences rating

Artelo Biosciences Reports Q1 2025 Earnings

Artelo Biosciences released FY2025 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -4.34 (forecast USD -0.78)

Artelo Biosciences expected to lose 13 cents per share, target price at $5.50

Artelo Biosciences Announces Effective Animal Trials for Psoriasis Candidate ART26.12

Artelo Biosciences released FY2024 Q4 earnings on March 3, 2025 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -6.9683 (forecast USD -2.62)

Artelo Biosciences released FY2024 annual earnings on March 3, 2025 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -18.2922 (forecast USD -11.82)

Artelo Biosciences released FY2024 9 Months Earnings on November 12 EST, with actual revenue of USD 0 and EPS of USD -11.2863

Artelo Biosciences released FY2024 Q3 earnings on November 12 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -2.104 (forecast USD -4.76)

Artelo Biosciences Announces Selection of FABP Inhibitor for NIH HEAL Initiative

Black Titan

Petmed Express

AXIL Brands

Agape ATP

SMX Security Matters

HeartBeam

Diamond Hill Investment

Leverage Shares 2X Long GEMI Daily ETF

Mawson Infrastructure

Grande

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap